Vertex


/


/our_dna_unraveled.html


/a-network-of-minds.html


/finances.html


/current-projects.html


http://investors.vrtx.com/press.cfm


/Resources.html


/destination-vertex.html

Adjust Font
Adjust Font

Welcome to Vertex Pharmaceuticals.

We believe that, just maybe, we can bring about a profound change in the treatment of serious diseases. This takes cutting-edge science and breakthrough therapies. We’ve built a worldwide community of top researchers and institutions that share our vision for change. With this approach, we think transformative solutions can be achieved even if there is never a “perfect cure.”

Careers

US Careers

EU Careers

Email & News Alerts

Events & Presentations

Recent News

Vertex Profile


About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.

Product Pipeline

Telaprevir, our lead drug candidate, targets hepatitis C virus (HCV) infection and is being evaluated in an international Phase 3 registration program. In addition, Vertex is developing HCV polymerase inhibitors that it acquired from ViroChem Pharma in early 2009 and plans to initiate a first clinical study combining telaprevir with a ViroChem HCV polymerase inhibitor in the second half of 2009.

Vertex is also developing two novel compounds aimed at the defective protein that causes cystic fibrosis (CF), known as the cystic fibrosis transmembrane conductance regulator (CFTR) protein. In May 2009, Vertex advanced VX-770, an investigational CFTR potentiator, into a Phase 3 registration program focused on patients with a specific mutation in the CFTR gene known as G551D, which accounts for 4 percent of the CF patient population. The company is also conducting a Phase 2a study of the investigational CFTR corrector VX-809 in patients with the F508del mutation, which is the most common mutation in the CF patient population.

Worldwide Locations

Cambridge, MA, USA
San Diego, CA, USA
Abingdon, Oxfordshire, UK
Coralville, IA, USA

Last Revised 06/23/09
  • Privacy Policy
  • Terms of Use
  • Site Map
  • Contact Us